Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy

Radiology

Volumn 264, Issue 1, 2012, Pages 68-77

  Stewart, Errol E ^a,b,e   Sun, Hongtao ^c   Chen, Xiaogang ^e   Schafer, Peter H ^d   Chen, Yong ^d   Garcia, Bertha M ^c   Lee, Ting Yim ^a,b,c,e  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d CELGENE CORPORATION   (United States)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; DIMETHYL SULFOXIDE; IOHEXOL; STERILE WATER; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; BLOOD VOLUME; CANCER ADJUVANT THERAPY; CANCER GRAFT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DYNAMIC CONTRAST MATERIAL ENHANCED COMPUTED TOMOGRAPHY; HEPATOGRAPHY; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER PERFUSION; LUNG METASTASIS; MALE; METASTASIS FREE SURVIVAL; NONHUMAN; PRIORITY JOURNAL; RABBIT; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; IOHEXOL; LIVER NEOPLASMS; MALE; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862704297     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12110674     Document Type: Article

References (46)

1. Berg ers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-410.
2. Yonenaga Y, Mori A, Onodera H, et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005;69(2):159-166. (Pubitemid 41376915)
3. Abramsson A, Berlin O, Papayan H, Paulin D, Shani M, Betsholtz C. Analysis of mural cell recruitment to tumor vessels. Circulation 2002;105(1):112-117. (Pubitemid 34049151)
4. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999;103(2):157-158. (Pubitemid 29053132)
5. Hellström M, Gerhardt H, Kalén M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153(3):543-553. (Pubitemid 34280141)
6. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685-693. (Pubitemid 36749217)
7. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160(3):985-1000. (Pubitemid 34224587)
8. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11(2 Pt 1):743-750. (Pubitemid 40116903)
9. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23(15):3502-3508.
10. Lee CG, Heijn M, di Tomaso E, et al. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565-5570.
11. Teicher BA, Holden SA, Ara G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and rea sponse to cytotoxic therapy. Int J Cancer 1995;61(5):732-737.
12. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Völcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236(6):461-466. (Pubitemid 28269042)
13. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23(3):319-321. (Pubitemid 32428043)
14. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-989. (Pubitemid 32937367)
15. Franco M, Man S, Chen L, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66(7):3639- 3648.
16. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 2006;12(11 Pt 1):3518-3524.
17. Ch'ang HJ, Hsu C, Chen CH, Chang YH, Chang JS, Chen LT. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012;82(2):817-825.
18. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 2004;6(6):529-531. (Pubitemid 40017694)
19. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60(5):1388- 1393. (Pubitemid 30152012)
20. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of antivascular therapy. Am J Pathol 2003;162(1):183-193. (Pubitemid 36042000)
21. Stewart EE, Chen X, Hadway J, Lee TY. Hepatic perfusion in a tumor model using DCE-CT: an accuracy and precision study. Phys Med Biol 2008;53(16):4249-4267.
22. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62(14):3909-3913. (Pubitemid 34791050)
23. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001;173(1):83-91. (Pubitemid 32907513)
24. Pauser S, Wagner S, Lippmann M, et al. Evaluation of efficient chemoembolization mixtures by magnetic resonance imaging therapy monitoring: an experimental study on the VX2 tumor in the rabbit liver. Cancer Res 1996;56(8):1863-1867. (Pubitemid 26118223)
25. Dal Lago L, Richter MF, Cancela AI, et al. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs 2003;21(3):359-366. (Pubitemid 37486337)
26. Gelman S, Fowler KC, Smith LR. Liver circulation and function during isoflurane and halothane anesthesia. Anesthesiology 1984;61(6):726-730. (Pubitemid 15223425)
27. Papadopulos F, Spinelli M, Valente S, et al. Common tasks in microscopic and ultrastructural image analysis using ImageJ. Ultrastruct Pathol 2007;31(6):401-407.
28. Burri PH, Tarek MR. A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec 1990;228(1):35-45. (Pubitemid 20263034)
29. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62. (Pubitemid 40093472)
30. Jain RK. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1997;4(1):1-23.
31. Stewart EE, Chen X, Hadway J, Lee TY. Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model. Radiology 2006;239(3):740-750. (Pubitemid 43830609)
32. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56(5):941-943. (Pubitemid 26065381)
33. Larson AC, Wang D, Atassi B, et al. Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma-feasibility of initial clinical translation. Radiology 2008;246(3):964-971.
34. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99(10):2037-2044.
35. de Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14(17):5548-5554.
36. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-147. (Pubitemid 38524883)
37. Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 2009;124(6):1293-1300.
38. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97(4):1042-1050. (Pubitemid 36173156)
39. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64(11):3731-3736. (Pubitemid 38697278)
40. Marin D, Nelson RC, Schindera ST, et al. Low-tube-voltage, high-tube-current multidetector abdominal CT: improved image quality and decreased radiation dose with adaptive statistical iterative reconstruction algorithm-initial clinical experience. Radiology 2010;254(1):145-153.
41. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328(25):1797-1801. (Pubitemid 23174709)
42. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30(1):17-25.
43. Cuenod C, Leconte I, Siauve N, et al. Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 2001;218(2):556-561. (Pubitemid 32121075)
44. Kan Z, Ivancev K, Lunderquist A, et al. In vivo microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to hepatic metastases. Radiology 1993;187(3):621-626. (Pubitemid 23155684)
45. Tello R, Crewson PE. Hypothesis testing II: means. Radiology 2003;227(1):1-4. (Pubitemid 36384171)
46. Bender R, Lange S. Multiple test procedures other than Bonferroni's deserve wider use. BMJ 1999;318(7183):600-601. (Pubitemid 29188972)